The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N05 | Psycholeptics | |
3
|
N05C | Hypnotics and sedatives | |
4
|
N05CF | Benzodiazepine related drugs | |
5
|
N05CF02 | Zolpidem |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 10 mg |
| Active Ingredient |
|---|
|
Zolpidem is an imidazopyridine which preferentially binds the omega-1 receptor subtype (also known as the benzodiazepine-1 subtype) which corresponds to GABA-A receptors containing the alpha-1 sub-unit, whereas benzodiazepines non-selectively bind both omega-1 and omega-2 subtypes. The modulation of the chloride anion channel via this receptor leads to the specific sedative effects demonstrated by zolpidem. These effects are reversed by the benzodiazepine antagonist flumazenil. |
| Document | Type | Information Source | |
|---|---|---|---|
| AMBIEN Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| EDLUAR Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| STILNOCT Coated tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| STILNOX Film-coated tablet | MPI, EU: SmPC | Web Search |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.